Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cyclin Dependent Kise 2 (p33 Protein Kise or Cell Division Protein Kise 2 or CDK2 or EC 2.7.11.22) - Overview
Cyclin Dependent Kise 2 (p33 Protein Kise or Cell Division Protein Kise 2 or CDK2 or EC 2.7.11.22) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Cyclin Dependent Kise 2 (p33 Protein Kise or Cell Division Protein Kise 2 or CDK2 or EC 2.7.11.22) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cyclin Dependent Kise 2 (p33 Protein Kise or Cell Division Protein Kise 2 or CDK2 or EC 2.7.11.22) - Companies Involved in Therapeutics Development
Cyclin Dependent Kise 2 (p33 Protein Kise or Cell Division Protein Kise 2 or CDK2 or EC 2.7.11.22) - Drug Profiles
Cyclin Dependent Kise 2 (p33 Protein Kise or Cell Division Protein Kise 2 or CDK2 or EC 2.7.11.22) - Dormant Products
Cyclin Dependent Kise 2 (p33 Protein Kise or Cell Division Protein Kise 2 or CDK2 or EC 2.7.11.22) - Discontinued Products
Cyclin Dependent Kise 2 (p33 Protein Kise or Cell Division Protein Kise 2 or CDK2 or EC 2.7.11.22) - Product Development Milestones
Featured News & Press Releases
Apr 12, 2022: Cyclacel Pharmaceuticals announces publication confirming fadraciclib suppresses MCL1 and synergizes with venetoclax in chronic lymphocytic leukemia
Mar 08, 2022: Blueprint Medicines to showcase poster presentation on BLU-222 at AACR Annual Meeting 2022
Dec 28, 2021: Regor Therapeutics announces U.S. FDA authorization to conduct Regor’s first-in-human clinical trial with the next generation targeted inhibitor RGT-419B for oncology
Nov 05, 2021: Cyclacel announces dosing of first patient in phase 1/2 study of oral fadraciclib in patients with leukemias or myelodysplastic syndromes
Jul 13, 2021: Cyclacel announces dosing of first patient in phase 1/2 study of oral fadraciclib in patients with advanced solid tumors and aggressive lymphomas
May 05, 2021: Tizia announces strategic initiative with Takawa Japan K.K., Pharma team, to identify a partner in Japan and other Asian countries for further clinical development of Milciclib in patients with advanced hepatocellular carcinoma
Jan 14, 2021: Adastra Pharmaceuticals, present at Iugural B. Riley Securities’ Oncology Investor Conference
Jan 13, 2021: Adastra Pharmaceuticals announces positive top-line data from phase 1b clinical trial of Zotiraciclib in the treatment of recurrent high-grade gliomas
Oct 26, 2020: Cyclacel presents phase 1 clinical data showing safety, anti-tumor activity and good oral bioavailability of fadraciclib in patients with advanced solid tumors at the EORTC-NCI-AACR Symposium 2020
Oct 06, 2020: ICR to study fadraciclib to treat paediatric neuroblastoma
Sep 21, 2020: Cyclacel announces Fadraciclib abstract selected for oral presentation in the Late Breaking and Best Proffered Paper session at the 32nd EORTC-NCI-AACR Symposium 2020
Aug 21, 2020: Tizia granted a patent on the use of milciclib in combition with tyrosine kise inhibitors for treatment of hepatocellular carcinoma and other cancers
Jul 13, 2020: Cyclacel’s clinical stage CDK2/9 inhibitor Fadraciclib targets key anti-apoptotic and oncogenic pathways in cancer
May 14, 2020: Tizia Lifesciences announces online publication of two abstracts at the American Society of Clinical Oncology (ASCO) reporting clinical activity and safety of Milciclib in patients with advanced hepatocellular carcinoma
May 11, 2020: Tizia Life Sciences announces publishing of two e-abstracts featuring its Miliciclib
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Apollo Therapeutics LLC, 2022
Pipeline by Astex Pharmaceuticals Inc, 2022
Pipeline by Aucentra Therapeutics Pty Ltd, 2022
Pipeline by BioTheryX Inc, 2022
Pipeline by Blueprint Medicines Corp, 2022
Pipeline by Cedilla Therapeutics, 2022
Pipeline by Cothera Bioscience Pty Ltd, 2022
Pipeline by Cyclacel Pharmaceuticals Inc, 2022
Pipeline by Incyclix Bio LLC, 2022
Pipeline by Incyte Corp, 2022
Pipeline by Monte Rosa Therapeutics Inc, 2022
Pipeline by Neosome Life Sciences LLC, 2022
Pipeline by Pfizer Inc, 2022
Pipeline by Plexium Inc, 2022
Pipeline by Prous Institute for Biomedical Research SA, 2022
Pipeline by Qilu Regor Therapeutics Inc, 2022
Pipeline by Relay Therapeutics Inc, 2022
Pipeline by Rhizen Pharmaceuticals SA, 2022
Pipeline by Rizen (Suzhou) Biosciences Co Ltd, 2022
Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022
Pipeline by Simcere Pharmaceutical Group Ltd, 2022
Pipeline by Ting Therapeutics LLC, 2022
Pipeline by Tiziana Life Sciences Plc, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Discontinued Products, 2022